Cabergoline

CLINICAL USE

  • Endocrine disorders
  • Adjunct to levodopa (with a decarboxylase inhibitor) in Parkinson’s disease
  • Inhibition/suppression of lactation

    DOSE IN NORMAL RENAL FUNCTION

  • Parkinson’s disease: 2–6 mg daily
  • Hyperprolactinaemic disorders: 0.25–2 mg weekly
  • Inhibition of lactation: single 1 mg dose during first day post partum
  • Suppression of lactation: 0.25 mg twice a day for 2 days

    PHARMACOKINETICS

  • Molecular weight                           :451.6
  • %Protein binding                           :41–42
  • %Excreted unchanged in urine     : 2–3
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :63–68 (healthy individuals), 79–115 (hyperprolactinaemic individuals)/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Dialysed. Dose as in normal renal function
  • HD                     :Dialysed. Dose as in normal renal function
  • HDF/high flux   :Dialysed. Dose as in normal renal function
  • CAV/VVHD      :Dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

  • 18% of radiolabelled dose is excreted as inactive metabolites in urine72% of dose is excreted in faeces
    • Tags:

    Related News

    ffddfd

    Hyperlipidemia